VSC.DE

4SC AG [VSC.DE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

VSC.DE Stock Summary

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

Earnings are expected to fall -100% next year

Profit margins (-34.33%) are lower than the previous year (-32.94%)

VSC.DE has less than 1 year of cash runway

In the News

VSC.DE Financial details

Company Rating

Neutral

Market Cap

150.7M

Income

-7.68M

Revenue

388K

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

20 Apr 2023

P/E

-2.01

Forward P/E

PEG

1.01

P/S

345.64

P/B

2.27

P/C

P/FCF

-16.06

Quick Ratio

15.89

Current Ratio

16.02

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.76

EPS next Y

EPS next Q

EPS this Y

49.47%

EPS next Y

EPS next 5Y

EPS last 5Y

-13.19%

Revenue last 5Y

-36.35%

Revenue Q/Q

EPS Q/Q

SMA20

50%

SMA50

50%

SMA100

Inst Own

Inst Trans

ROA

-91%

ROE

-73%

ROC

-0.89%

Gross Margin

64%

Oper. Margin

-3155%

Profit Margin

-3433%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.17-3.46

52W High

-0.67%

52W Low

+198%

RSI

Rel Volume

0.01

Avg Volume

2.23K

Volume

Perf Week

14.62%

Perf Month

119.12%

Perf Quarter

Perf Half Y

68.36%

Beta

Volatility

0.17%, 0.48%

Prev Close

Price

2.98

Change

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 2.23K
Market Capitalization 150.7M
Employee 33
CEO Dr. Jason Loveridge
Headquarters Planegg,BAYERN,DE
IPO Date 2008-02-25
Website http://www.4sc.de

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.